• MJHLS Brand Logo

© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

FDA Approves Biocon Biologics' Denosumab Biosimilars: Bosaya and Aukelso

September 18, 2025

The FDA has approved Bosaya and Aukelso, expanding affordable denosumab biosimilars for osteoporosis and bone-related cancers and enhancing treatment options.

BioRationality: No More Clinical Efficacy Testing for Biosimilars, Going From Biosimilars to Biogenerics

September 16, 2025

Real-World Evidence Supports Biosimilar HLX02 in Metastatic Breast Cancer

September 11, 2025

Australian Study Reveals Significant Cost Savings and Market Impact From Biosimilars

September 10, 2025

Switch to Biosimilar Adalimumab Found Safe and Cost-Saving for Patients With IBD

September 09, 2025

Featured Content

SYSA1902 Biosimilar Proves Equivalent to Reference Ustekinumab in Plaque Psoriasis

September 8th 2025

By Skylar Jeremias

Article

A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque psoriasis, expanding patient options.

The Top 5 Biosimilar Articles for the Week of September 1

September 5th 2025

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of September 1, 2025.

Japanese Trial Supports Widespread Use, Safety of Infliximab Biosimilar Use

September 4th 2025

By Skylar Jeremias

Article

A recent Japanese study confirms that switching from originator infliximab to biosimilars maintains remission in patients who have rheumatoid arthritis, enhancing treatment accessibility.

Patients With nAMD Maintain Vision on Aflibercept Biosimilar ABP 938

September 3rd 2025

By Skylar Jeremias

Article

A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration (nAMD), enhancing patient access to treatment.

Biosimilars News Roundup: August 2025

September 2nd 2025

By Skylar Jeremias

Article

August 2025 brought significant advancements in biosimilars, including financial successes, new product launches, and research on ongoing challenges in market access.

FDA Greenlights Fifth Pair of Denosumab Biosimilars: Bildyos and Bilprevda

September 2nd 2025

By Skylar Jeremias

Article

New denosumab biosimilars, Bildyos and Bilprevda, enhance access to affordable osteoporosis and bone disease treatments, promising significant patient benefits.

The Top 5 Biosimilar Articles for the Week of August 25

August 29th 2025

By Skylar Jeremias

Video

Here are the top 5 biosimilar articles for the week of August 25, 2025.

Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27th 2025

By Skylar Jeremias

Article

Alvotech achieves a remarkable financial turnaround in 2025, reporting a net profit driven by strong biosimilar sales and strategic partnerships.

Canadian RWE Shows Comparable Outcomes Between Etanercept Biosimilars, Originator

August 26th 2025

By Skylar Jeremias

Article

Canadian study reveals no significant differences in remission outcomes between etanercept biosimilars and the originator, Enbrel, for rheumatoid arthritis patients.

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

August 25th 2025

By Rose McNulty

Article

New research confirms the romiplostim biosimilar GP40141 offers comparable efficacy and safety for treating immune thrombocytopenia, enhancing treatment accessibility.